Magnesium sulfate (MgSO 4 ) , has been shown to be the most efficient treatment for eclamptic seizures. 1 While the mechanism of action still remains unclear, proposals include vasodilation, decreased permeability of the blood-brain barrier, decreased neuroinflammation and anticonvulsant mechanisms by way of acting as an N-methyl-D-aspartate receptor (NMDA) antagonist. 2,3 MgSO 4 is also used as a prophylaxis in preeclampsia when seizures are deemed imminent. There is however no clear consensus worldwide concerning indication for treatment. Eclampsia is not always preceded by severe preeclampsia and although there are known prodromal symptoms such as severe headache and visual disturbances, many women are asymptomatic immediately prior to their seizure. 4 Magnetic resonance imaging and magnetic resonance spectroscopy (MRS) have dramatically increased our ability to noninvasively study morphological as well as metabolic and functional changes in different tissues. Importantly for the aim of the present study, intracellular Mg 2+ levels can be quantified using phosphorous MR spectroscopy ( 31 P-MRS). 5 Up to date, only one 31 P-MRS study focusing on the brain in preeclampsia has been published so far, but the included study population was very small and the technique vaguely described. 6 However, the authors found lower cerebral Mg 2+ levels in normal pregnancy compared to nonpregnant controls and even lower levels in study patients with preeclampsia. No information was available regarding cerebral symptoms.
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In this cross-sectional study, we aimed to estimate cerebral Mg 2+ levels in women with preeclampsia, women with normal pregnancies and nonpregnant women. We hypothesized that lower Mg 2+ levels would correlate with cerebral symptoms in women with preeclampsia.
MATERIAL AND METHODS

Study design and population
The study participants in this cross-sectional study were recruited in Uppsala, Sweden during 2013-2016. Uppsala University Hospital is a tertiary referral centre with approximately 4,000 deliveries per year. General exclusion criteria were chronic hypertension, diabetes mellitus, preexisting renal disease, or contraindications for magnetic resonance imaging, e.g., claustrophobia or pacemaker. Only singleton pregnancies were included.
Cases were 30 women with preeclampsia who were recruited from the obstetric ward or outpatient clinic. Preeclampsia was defined as de novo hypertension after 20 weeks of gestation in combination with proteinuria. Hypertension was defined as systolic blood pressure (BP) of ≥140 mm Hg and/or diastolic BP of ≥90 mm Hg measured on 2 subsequent occasions with at least 6 hours apart and proteinuria as ≥2+ on a dipstick or ≥300 mg/24 hour in a urine collection. Preeclampsia was defined as severe, when BP was ≥160 mm Hg systolic and/or ≥110 mm Hg diastolic; or if HELLP-syndrome was present. This is according to the recommendations from the International Society for studies on Hypertension in Pregnancy (ISSHP). 7 Only women with singleton pregnancies and a gestational length between 22 + 0 and 41 + 6 were eligible. They also had to be clinically stable enough to be transported to the MR facility. None of the women were treated with MgSO 4 . Every woman diagnosed with preeclampsia, either admitted or monitored as an outpatient that came to the main researcher's (M.N.) knowledge, was approached regarding study participation. Only a small fraction of respondents abstained participation in the study, most often due to fear of claustrophobia. The included women were subsequently followed through their medical record and data on infant birth weight, mode of delivery, and gestational age at delivery was noted. Small for gestational age was defined as a birth weight below 2 SDs from the sexspecific national reference curve. 8 Gestational age was estimated with an early second trimester ultrasound.
We recruited 2 control groups: normal pregnant women in corresponding gestational age as the preeclampsia group at inclusion and a nonpregnant group. The normal pregnant group included 32 women and they were recruited through information posters at antenatal outpatient clinics in Uppsala and at university facilities. A normal pregnancy was defined as a normotensive pregnancy resulting in term delivery (gestational week ≥ 37) of an infant with normal birth weight (±2 SDs of the mean birth weight for gestational age and sex). 8 This group was also followed through their medical record and women who subsequently developed preeclampsia were excluded. The nonpregnant control group included 11 women, both parous and nulliparous. These participants were recruited through Facebook and local networks. In addition to the general exclusion criteria, women with prior history of preeclampsia or gestational hypertension were not included in the control groups.
All participants underwent BP measurement, blood and urine sampling, and MRS examination within a 12-hour period after enrollment in the study. The BP recording closest to the MRS examination was used (0.25-4 hours). Systolic and diastolic BPs were measured in supine position in the right arm after a 15-minute rest. A manual sphygmomanometer (Unmedico CE) with appropriate cuff size depending on arm circumference was used. The plasma samples were collected in Vacutainer tubes with Lithium Heparin (Becton, Dickinson, Franklin Lakes, NJ). The samples were centrifuged for 10 minutes at 1,500 g and the plasma was immediately frozen at −70° C for later analysis. Plasma Mg 2+ levels were analyzed on a BS380 instrument (Mindray, Shenzhen, China) with reagent (3P68) from Abbott Laboratories (Abbott Park, IL). 9 Fresh midstream urine samples were collected and analyzed with a Combur 9 test (Roche) or Clinitek Status Analyzer (Siemens). Directly prior to the MRS, an interview was conducted with questions regarding cerebral symptoms. This covered detailed questions regarding headache and visual disturbances, including scotomas, blurred vision, and diplopia occurring in the last 3 days.
MAGNETIC RESONANCE SPECTROSCOPY
Data acquisition
Cases and controls were scanned on a 1.5 Tesla MR system (Achieva, Philips Healthcare, The Netherlands). The whole-body RF-coil served for imaging and transmit-receiver quadrature head coil (diameter 29 cm, length 25 cm) was used for phosphorous spectroscopy ( 31 P-MRS). Morphological images were first obtained for purpose of MRS planning. This was performed using T 2 -weighted multishot turbo spin-echo sequences in parasagittal, coronal, and transverse planes (acquisition pixel size 1.5 × 1.9 mm 2 , slice thickness, 6 mm). Single-voxel 31 P-MRS was performed using image-selected in vivo spectroscopy (ISIS) localization scheme 9 with a spectral bandwidth 1,500 Hz, repetition time 3,500 ms, 1,024 points, and 256 acquisitions. Iterative firstorder shimming improved magnetic field inhomogeneity inside the volume of interest (VOI; voxel). Typical voxel size was 35 × 75 × 50 mm 3 with a position in the parieto-occipital region ( Figure 1 ). Quality of the spectra was improved by proton ( 1 H) broad band decoupling and nuclear Overhauser enhancement. The whole-body coil was used for this purpose. Proton decoupling consisted of standard WALTZ-4 cycle. The mixing time of nuclear Overhauser enhancement broad band irradiation was 2,400 ms. The net measurement time was 15 minutes 3 seconds.
Spectrum processing
Magnetic resonance user interface software package 10 was used for spectrum processing. The spectra were fitted using AMARES method in time domain. 11 No apodization of the free induction decay to improve the signal-to-noise ratio (SNR) was used during fitting. Nevertheless, for presentation purpose (Figure 2 ), a Lorentzian apodization corresponding to 2 Hz line broadening was applied. Phosphocreatine peak was placed to 0 ppm. Multiplication (weighting) of the first 20 FID points with a quarter-sine wave was used to remove the broad background signal that typically underlines 31 P brain spectra. Thus, the broad component of the signal became part of the residue. Spectral intensities of following metabolites were fitted by Lorentzians: phosphomonoesters, inorganic phosphate, phosphodiesters, phosphocreatine, γ-, α-, and β-adenosine triphosphate (Figure 2 ). Cytosolic concentration of free magnesium (Mg 2+ ) was calculated from the chemical shift between phosphocreatine and β-adenosine triphosphate using the equation of Iotti et al. 5 Since position of β-adenosine triphosphate triplet can be difficult to determine in individual spectra due to low SNR, spectra from each group of the volunteers (preeclampsia, normal pregnant, and nonpregnant) were also averaged ( Figure 2 ) and mean Mg 2+ levels of each group were computed from these spectra. The physicist analyzing the MRS levels was not aware of which study group the woman belonged to.
Statistics
Frequency histograms and Shapiro-Wilk's test was used to test cerebral and plasma Mg 2+ levels in each study group for normal distribution. Thereafter, we used analysis of variance for overall comparisons of means and Tukey's test for multiple pair-wise comparisons. Chi-square and Fisher's exact tests were used for comparisons between categorical variables. Spearman's correlation test was assessed when we estimated correlations between cerebral Mg 2+ levels and maternal age, body mass index, and gestational length at examination in the normal pregnant population, as well as between cerebral and plasma Mg 2+ levels and cerebral Mg 2+ levels and cerebral symptoms in women with preeclampsia. All significance tests were 2-tailed. P <0.05 was considered to denote a statistically significant difference. All analyses were performed using IBM SPSS Statistics 23 (IBM SPSS, Chicago, IL).
Ethics
The study was approved by the Regional Ethical Review Board in Uppsala, Sweden, and informed consent was obtained from each woman participating in the study.
RESULTS
Of the 73 included women, 2 women with preeclampsia did not complete the 31 P-MRS examination due to discomfort. Four normal pregnant controls were excluded since 2 of them developed preeclampsia after their inclusion in the study, one had a spectrum where intracellular Mg 2+ could not be calculated and one had a level of Mg 2+ that was an extreme outlier (>3 interquartile range) The final analysis was based on spectra from 67 women (28 preeclampsia, 28 normal pregnant, and 11 nonpregnant). Table 1 presents the clinical characteristics of the study population. The nonpregnant group was significantly younger than the pregnant participants, but there was no difference in maternal age between the preeclampsia and normal pregnant groups, 29.4 and 32.3 years, respectively. Both the normal pregnant and the nonpregnant groups had lower mean body mass indexes than the preeclampsia group, P = 0.048 and P = 0.001, respectively. As expected the proportion of primiparas was high in the preeclampsia group, 82%. In contrast, in our normal pregnant group most women were parous.
In Table 2 , the preeclampsia group is further described. The mean gestational week at onset of preeclampsia was 33.2 weeks, with a range from 25 to 41 weeks. Most women had antihypertensive treatment (21/28), predominantly with a monotherapy of Labetalol, (n = 18). At examination, 8 women were found to have severe preeclampsia, a number that increased to 15 at the time of delivery. Mode of delivery was mostly cesarean delivery (16/28) and 7 women gave birth to infants small for gestational age. No woman was treated with MgSO 4 . Figure 3 shows a scatter plot of cerebral Mg 2+ levels for the 3 study groups. The mean Mg 2+ level was 0.12 ± 0.02 mM in the preeclampsia group, 0.14 ± 0.03 mM in the normal pregnant group and 0.14 ± 0.03 mM in the nonpregnant group. This yielded a significant difference between groups (analysis of variance; P = 0.04) where women with preeclampsia had a significantly lower cerebral level of Mg 2+ compared to women with normal pregnancy (P = 0.04). There was no significant difference in cerebral Mg 2+ content between the preeclampsia and nonpregnant group (P = 0.22), nor between normal pregnant and nonpregnant women (P = 0.98). It should be noted, however, that accuracy of Mg 2+ concentrations estimated from individual spectra suffer from the lower SNR of β-adenosine triphosphate resonances. Therefore, we also calculated cerebral Mg 2+ levels from the averaged spectra of each study group. In the preeclampsia group, the cerebral Mg 2+ level was 0.12 mM, in the normal pregnant group 0.15 mM, and in the nonpregnant group 0.17 mM. Since each study group was represented by single (averaged) spectrum, significance of differences between groups was not possible to compute. Table 3 presents correlations between cerebral Mg 2+ levels and cerebral symptoms in women with preeclampsia. There was a significant correlation between Mg 2+ levels and presence of visual disturbances (P = 0.04). However, Mg 2+ levels did not correlate with presence of headache.
Supplementary Figure 1 illustrates plasma Mg 2+ levels in each study group. Nonpregnant women had a higher plasma Mg 2+ level than normal pregnancy (0.76 ± 0.06 mM vs. 0.68 ± 0.06 mM, P = 0.005) and a borderline higher level than the preeclampsia group (0.70 ± 0.08 mM, P = 0.054). Women with preeclampsia and the normal pregnant group did not differ in plasma Mg 2+ levels (P = 0.479).
Cerebral Mg 2+ levels did not differ between those with antihypertensive treatment and those without (0.12 ± 0.03 mM vs. 0.12 ± 0.02 mM, P = 0.92). Cerebral Mg 2+ levels did not Severe preeclampsia a , n (%) 15 (54%)
Vaginal/cesarean delivery (n/n) 12/16
Infant small for gestational age b , n (%) 7 (25%) a According to the guidelines from the International Society for the study of Hypertension in Pregnancy (ISSHP).
b Birthweight deviation >22% below the sex-specific reference curve for gestational age 8 . At examination
Gestational week, mean ± SD 33.6 ± 4.6 33.0 ± 5.1 n.s.
Blood pressure (mm Hg)
Systolic, mean ± SD 146 ± 10 112 ± 8 112 ± 6 <0.001
Diastolic, mean ± SD 93 ± 11 68 ± 8 67 ± 5 <0.001
Abbreviations: BMI, body mass index; n.s, non significant. a Early pregnancy BMI for the pregnant study groups.
correlate with maternal age (P = 0.50), body mass index (P = 0.90) or gestational age at examination (P = 0.43). In the preeclampsia group, the cerebral and plasma Mg 2+ levels did not correlate (P = 0.60) (results are not shown in tables).
DISCUSSION
In this MRS study, we found lower cerebral Mg 2+ levels in women with preeclampsia compared to normal pregnant women. Furthermore, we found a novel correlation between visual disturbances in women with preeclampsia and a lower cerebral Mg 2+ . Our VOI was placed partly in the medial occipital lobe, the site of the primary visual cortex, which also strengthens the argument that Mg 2+ plays a central role in the pathophysiology of eclampsia/preeclampsia.
To our knowledge, only one prior study has used 31 P-MRS to examine the maternal brain in preeclampsia. 6 The paper was published by Resnick et al. in 2004 , and their results are consistent with ours regarding a lower cerebral Mg 2+ level in women with preeclampsia compared to normal pregnant women. There are however differences in absolute levels of intracellular Mg 2+ between their study and ours. For normal pregnant women Resnick et al. reported an average Mg 2+ level of 0.34 mM in contrast to our 0.14 mM. This is most probably explained by differences in methodologies. They used an equation described by Gupta et al. in 1984, 12 whereas we have used the approach further developed by Iotti et al. 5 In the study by Iotti, they reported cytosolic Mg 2+ of 0.182 mM from an averaged spectra of all 36 participants which is lower than previously published. The difference in results can be explained by the different models estimating Mg 2+ used, where the equation by Iotti et al. considers more species that bind Mg 2+ than earlier reports. When we estimated the Mg 2+ level based on the average spectrum from all nonpregnant women, our result was 0.17 mM, i.e., very similar to Iotti et al. When comparing Mg 2+ levels calculated from individual spectra, we could not replicate Resnick et al. 's finding of reduced Mg 2+ levels in normal pregnant women compared to nonpregnant women. However, when we compared Mg 2+ levels calculated from the averaged spectra of the 3 groups, our results are consistent with Resnick et al. 6 also in this regard. Results from averaged spectra may be more reliable since this increases the SNR. On the other hand, no formal significance tests on differences between groups can be performed using this technique.
Besides using different calibration techniques, there are other differences between our study and Resnick et al. Their study was smaller, with a total of 30 patients whereof only 7 with preeclampsia. No patients with medication were included, thereby excluding those with a more severe disease. No information regarding cerebral symptoms was given. There are also differences in MRS methodology. We have used a voxel localization technique (ISIS) 9 to be able to determine the VOI with high accuracy. In the previous study, the size and position of their VOI was not clearly described. We focused on the parieto-occipital region since this has been shown to be the most commonly affected regions in posterior reversible encephalopathy syndrome (PRES). 13 This syndrome is a combination of edema in predominantly the occipital and parietal lobes on magnetic resonance imaging and clinical symptoms of headache, altered mental state, nausea, visual disturbance, and seizures. PRES is seen in a number of conditions, including eclampsia and preeclampsia. 14 Our finding that women with preeclampsia have lower cerebral Mg 2+ levels than normal pregnant women is interesting considering that the most effective treatment and prophylaxis of eclampsia is intravenous MgSO 4 . Although the exact mechanisms of action is not fully understood, it is known that Mg 2+ can act as an antagonist to the glutamate receptor NMDA in the brain. 2 With reduced Mg 2+ levels, less NMDA receptors are blocked and more can be opened at a relatively low membrane potential causing hyperexcitability of neurons, lowering the threshold for seizures. In an earlier study of subarachnoid hemorrhage, an increase in cerebral intracellular Mg 2+ by 0.018 mM was observed in subjects treated with intravenous MgSO 4 . 14 In our study, the average difference in cerebral Mg 2+ levels between women with preeclampsia and women with normal pregnancy was 0.02mM, a difference that could indicate clinical importance based on the results above. There is however no data regarding the effect on cerebral Mg 2+ by treatment with MgSO 4 in preeclamptic women. We can only speculate if the observed failure of seizure prophylaxis/treatment in some preeclamptic/eclamptic women is due to inadequately raised cerebral Mg 2+ levels or if it is caused by other seizure generating factors.
An important strength of this study is our detailed information regarding cerebral symptoms, such as headache and visual disturbances, immediately preceding the MR examination. This gives us a unique opportunity to link clinical presentation with cerebral Mg 2+ levels. Although larger than previously reported studies, our cohort consists of relatively few women. Our measurements of Mg 2+ are limited to one VOI. It would be interesting to proceed to examine other regions in the brain and compare results. Due to concerns of possible negative effects on the fetus at higher magnetic field levels, we were limited to examination at 1.5T. Imaging at 3T would improve both the SNR and the spectral resolution, both of which would increase measurement accuracy.
Since participants in the study needed to be transported to the MR scanner, those with an unstable condition could not be included, possibly underestimating the differences between groups. A high proportion of women with preeclampsia were on antihypertensive treatment, mostly a monotherapy with Labetalol. Labetalol has been shown not to affect the cerebral blood flow or autoregulation, but possibly lowering the cerebral perfusion pressure. 15, 16 If this also affects the cerebral Mg 2+ levels is not known.
In conclusion, we have found that cerebral Mg 2+ levels are lower in preeclampsia, an observation that agrees with the fact that MgSO 4 is the best available prophylaxis for seizures, i.e., eclampsia. The finding of lower Mg 2+ levels in the medial parieto-occipital region of women with preeclampsia and visual disturbances could indicate that these symptoms should warrant a closer monitoring and a consideration to use MgSO 4 -prophylaxis.
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